Japanese Journal of Cancer and Chemotherapy最新文献_第9页

[Microphysiological System(MPS)for Drug Research, the Current Situation and the Future]. 微生理系统（MPS）在药物研究中的应用现状与未来

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-04-01

Osamu Ando, Yuzuru Ito

{"title":"[Microphysiological System(MPS)for Drug Research, the Current Situation and the Future].","authors":"Osamu Ando, Yuzuru Ito","doi":"","DOIUrl":"","url":null,"abstract":"The development of new in vitro cell culture systems, the microphysiological systems(MPSs), is progressing rapidly around the world. MPS is a biomimetic cell culture system that recapitulate tissue biology(patho)physiologically using clinically derived specimens, organoids, or differentiated cells from stem cells on a culture device with circulation and detection devices. New disease model systems are being constructed using MPS and are used as proof-of-concept and drug evaluation systems, and are attracting attention as an approach to addressing unmet medical needs. In conventional anti-cancer drug research, in vitro culture systems are mainly used to evaluate the growth inhibitory potential of cancer cell line monocultures. On the other hand, MPS has made it possible to monitor cancer pathology, malignant traits, and pharmacological activity, such as reproduction of the cancer niche, interactions between cancer cells and various stroma in the tumor microenvironment, cancer cell movement, and immune cell accumulation in cancer tissue. MPS is also used to evaluate safety and adverse effects and pharmacokinetics, which are essential for anticancer drug development. Various MPSs have been developed and reported for these purposes also in Japan, MPS technology is being developed, including for use in the regulatory process for non-clinical studies. Through these efforts, it is expected to lead to innovation in drug discovery in the field of oncology.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 4","pages":"287-293"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143999777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[A Case of cy1 Advanced Gastric Cancer That Achieved CR after Chemotherapy Via an Enterostomy]. [1例cy1晚期胃癌经肠造口化疗后达到CR]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-04-01

Hidetaka A Ono, Yohei Ota, Hirokazu Suwa, Kazunori Nojiri, Kenichi Yoshida, Hidenobu Masui, Kaoru Nagahori

引用次数: 0

[A Therapeutic Strategy Targeting Virus-Antigen in Cancer Treatment]. 一种针对病毒抗原的肿瘤治疗策略

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-04-01

Tomohiro Enokida

引用次数: 0

[A Case of Pulmonary Tuberculosis Developed During Neoadjuvant Chemotherapy for HER2-Enriched Breast Cancer]. 【her2富集型乳腺癌新辅助化疗中发生肺结核1例】。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-03-01

Yoko Mizuyama, Tsutomu Takashima

{"title":"[A Case of Pulmonary Tuberculosis Developed During Neoadjuvant Chemotherapy for HER2-Enriched Breast Cancer].","authors":"Yoko Mizuyama, Tsutomu Takashima","doi":"","DOIUrl":"","url":null,"abstract":"In the 1990s, the number of newly registered tuberculosis patients in Japan was about 40,000 per year. It has been gradually decreasing and the number of new patients became 10,235 in 2022 with the incidence rate of 8.2 per 100,000 population. However it is still occasionally encountered even in recent years. Herein, we report a case of human epidermal growth factor receptor 2(HER2)-enriched breast cancer patient developed pulmonary tuberculosis just after finishing neoadjuvant chemotherapy and was successfully treated for both disease simultaneously. A 68 years old woman presented due to right breast mass was diagnosed with hormonal receptor-negative, HER2-positive invasive ductal carcinoma. Neoadjuvant chemotherapy with paclitaxel, trastuzumab and pertuzumab was started. After 12 courses of chemotherapy, CT scan revealed disappearance of the right breast tumor and infiltrating shadow in the left lower lung field. Sputum polymerase chain reaction test for tuberculosis was positive. Anti-tuberculosis chemotherapy was started. Four days after starting isoniazid, partial mastectomy was performed under local anesthesia and radiation therapy for the breast was omitted. There are no signs of recurrence of breast cancer and pulmonary tuberculosis for 5 years. Chemotherapy for breast cancer and premedication with corticosteroid may have inhibited cellular immunity, causing endogenous relapse of tuberculosis.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 3","pages":"252-254"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Partial Nephrectomy and Focal Therapy in Small Renal Tumors]. [小肾肿瘤的肾部分切除术和病灶治疗]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-03-01

Yoshiyuki Matsui

{"title":"[Partial Nephrectomy and Focal Therapy in Small Renal Tumors].","authors":"Yoshiyuki Matsui","doi":"","DOIUrl":"","url":null,"abstract":"With the increasing use of robot-assisted surgery, partial nephrectomy is recommended for small renal tumors(T1a)with a tumor size of 4 cm or less and is now considered a standard treatment. However, with the rise in incidental detection of small renal tumors during routine screenings, especially in elderly patients or those with comorbidities who may hesitate to undergo general anesthesia, there is a growing need for alternative treatments such as focal therapy to partial nephrectomy. The main methods of focal therapy include ablation techniques such as cryotherapy and radiofrequency ablation. Recently, stereotactic body radiotherapy has also been approved for insurance coverage, emerging as a minimally invasive option for renal cell carcinoma with a tumor size of 5 cm or less. Additionally, although not a focal therapy, active surveillance is also considered an effective option for very small renal tumors. Among these various treatment options, shared decision making between patients and healthcare providers, considering factors such as tumor characteristics and patient-specific conditions, is considered crucial in determining the appropriate treatment strategy for small renal tumors. In the absence of large-scale prospective comparative trials on partial nephrectomy, ablation therapy, stereotactic radiotherapy, and active surveillance, this paper provides an overview of the characteristics of each treatment modality and their respective outcomes and discusses the future perspectives in the treatment of small renal tumors.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 3","pages":"205-209"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[A Case of an Older Patient with MSI-High Colorectal Cancer with Distant Lymph Node Metastasis Successfully Treated with Pembrolizumab]. [彭博利珠单抗成功治疗一例 MSI 高、伴有远处淋巴结转移的老年结直肠癌患者】。］

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-03-01

Shintaro Takeda, Yasushi Yoshida, Tomoaki Noritomi, Jun Yanagisawa, Mitsuaki Morimoto, Hiroki Ureshino, Shuhei Ito, Fuminori Ishii, Kazune Komiya, Yasuhito Hosoda, Ren Nakamura, Kyohei Sakamoto, Yutaro Nakagawa, Kozue Nakahara

{"title":"[A Case of an Older Patient with MSI-High Colorectal Cancer with Distant Lymph Node Metastasis Successfully Treated with Pembrolizumab].","authors":"Shintaro Takeda, Yasushi Yoshida, Tomoaki Noritomi, Jun Yanagisawa, Mitsuaki Morimoto, Hiroki Ureshino, Shuhei Ito, Fuminori Ishii, Kazune Komiya, Yasuhito Hosoda, Ren Nakamura, Kyohei Sakamoto, Yutaro Nakagawa, Kozue Nakahara","doi":"","DOIUrl":"","url":null,"abstract":"The patient was a 90-year-old man with a PS score of 0 and no underlying disease. He visited our hospital with a fever and was diagnosed with cancer of the ascending colon with abscess formation due to retroperitoneal perforation. First, he underwent ileostomy with double orifices and abscess puncture drainage, followed by right semicolon resection plus ileostomy closure to resect the primary tumor. Three months after the surgery, metastases were found in the left cervical supraclavicular and periaortic lymph nodes. The primary tumor was a poorly differentiated adenocarcinoma, RAS wild, BRAF mutation(+), and MSI-high(+). Therefore, pembrolizumab therapy was initiated, which resulted in a complete response(CR) at the end of 6 courses. After 2 years of pembrolizumab treatment, the patient's CR status was maintained, with only Grade 1 hypothyroidism. We believe that pembrolizumab therapy for MSI-high, unresectable, advanced, recurrent colorectal cancer is useful in older patients with good PS, no major underlying disease, and a medical system that can respond to irAE.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 3","pages":"258-259"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Resection of Oligometastasis Liver Metastases from Breast Cancer-Two-Case Report]. [乳腺癌寡转移肝转移灶切除术--两例报告]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-03-01

Yusuke Nishio, Satoshi Matsukuma, Shigeru Yamamoto, Masaki Iwado, Hiroaki Yamatani, Daiki Haraguchi, Atomu Suzuki, Naohiro Yamamoto, Sota Yoshimine, Kazuhisa Tokuno, Toru Kawaoka, Hisashi Sakano, Yuji Fujita, Norio Akiyama

{"title":"[Resection of Oligometastasis Liver Metastases from Breast Cancer-Two-Case Report].","authors":"Yusuke Nishio, Satoshi Matsukuma, Shigeru Yamamoto, Masaki Iwado, Hiroaki Yamatani, Daiki Haraguchi, Atomu Suzuki, Naohiro Yamamoto, Sota Yoshimine, Kazuhisa Tokuno, Toru Kawaoka, Hisashi Sakano, Yuji Fujita, Norio Akiyama","doi":"","DOIUrl":"","url":null,"abstract":"Resection of liver metastases from breast cancer is not widely accepted because the survival benefit of surgery has not been demonstrated. We report the cases of 2 patients who underwent resection of liver metastases from breast cancer. Case 1: This was a female patient in her 50s with synchronous metastasis of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Resection was performed since the patient had exhausted all anti-HER2 therapies and had only a single liver metastasis. Immunohistochemical staining results of the resected specimens showed HER2 negativity. The patient had no recurrence 5 months postoperatively and received adjuvant chemotherapy with capecitabine. Case 2: This was a female patient in her 70s with metachronous metastasis of hormone receptor-positive disease. A single liver metastasis occurred 28 years after the primary tumor resection. During the 2-year hormone therapy, no new lesions appeared, and the tumor was stable; therefore, resection was performed. The resected specimen showed a complete pathological response. Furthermore, the patient has been recurrence-free for 1 year without any therapy.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 3","pages":"260-262"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Bladder Preservation Therapy for Bladder Cancer]. [膀胱癌的膀胱保存治疗]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-03-01

Hajime Tanaka, Yasuhisa Fujii

{"title":"[Bladder Preservation Therapy for Bladder Cancer].","authors":"Hajime Tanaka, Yasuhisa Fujii","doi":"","DOIUrl":"","url":null,"abstract":"Bladder cancer is classified into non-muscle-invasive bladder cancer(NMIBC)and muscle-invasive bladder cancer(MIBC).The prognosis for patients with NMIBC is generally favorable, and initial treatment for NMIBC typically involves transurethral resection of bladder tumor(TURBT), along with bladder instillation therapy based on risk stratification, with the goal of controlling the cancer while preserving the bladder. For cases at high risk of recurrence or progression, Bacillus Calmette-Guérin(BCG)intravesical therapy is used to prevent these events and ultimately avoid radical cystectomy. However, some patients exhibit BCG-unresponsive disease, defined as high-grade cancer persisting or recurring early after adequate BCG treatment. For BCG-unresponsive NMIBC, radical cystectomy is typically considered. However, recent advances are focused on the development of novel treatments aimed at bladder preservation in this patient population, offering hope for further progress in the future. The standard treatment for MIBC is radical cystectomy, but there is a certain number of patients who are either unfit for or unwilling to undergo this procedure. Addressing treatment options for these patients remains a significant unmet need. Recently, bladder preservation therapies using a multimodal approach, including trimodality therapy, have emerged as potential treatment options for MIBC. Appropriate patient selection, as well as further refinement and standardization of treatment protocols, remain key challenges.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 3","pages":"217-223"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Laparoscopic Proximal Sigmoid Colon Cancer Surgery Using Surgical-Assisted CT Colonography]. [利用手术辅助 CT 结肠造影进行腹腔镜乙状结肠近端癌手术]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-03-01

Kazuo Narushima, Toru Tonooka, Hiroaki Soda, Hiroyuki Amagai, Satoshi Chiba, Hiroshi Suito, Tetsuro Isozaki, Naoki Kuwayama, Kiyohiko Shuto, Mikito Mori, Masayuki Kano, Yoshihiro Nabeya

{"title":"[Laparoscopic Proximal Sigmoid Colon Cancer Surgery Using Surgical-Assisted CT Colonography].","authors":"Kazuo Narushima, Toru Tonooka, Hiroaki Soda, Hiroyuki Amagai, Satoshi Chiba, Hiroshi Suito, Tetsuro Isozaki, Naoki Kuwayama, Kiyohiko Shuto, Mikito Mori, Masayuki Kano, Yoshihiro Nabeya","doi":"","DOIUrl":"","url":null,"abstract":"Background and purpose: Preoperative understanding of the vascular morphology is important for preservation of the distal sigmoid colon and intraluminal processing of the mesentery in laparoscopic proximal sigmoid colon cancer surgery. We report a case of laparoscopic proximal sigmoid colon cancer surgery using sophisticated surgical-assisted CT colonography (CTC). The surgical-assisted CTC was created by combining a CTC created using SYNAPSE VINCENT and a vascular 3D-CT.Patient and method: The patient was a woman in 80s with proximal sigmoid colon cancer, cT1bN0M0, cStage Ⅰ. The patient had a history of ascending colon cancer surgery. Contrast-enhanced CTC was performed preoperatively, and 3D-CT images(CTC, arterial 3D-CT, and venous 3D-CT)were created by Workstation(SYNAPSE VINCENT®, FUJIFILM).Result: Using surgical-assisted CTC, D3 lymph node dissection, in which only the dominant artery, the first and second sigmoid colon artery, and its companion veins were processed, and enterotomy and mesenterotomy line at 10 cm on the oral and anal sides were simulated. Intraoperatively, surgery was performed as planned using surgical-assisted CTC as navigation images. The operative time was 197 minutes, and the blood loss was 30 g. The patient was discharged from the hospital on the 8th day without any postoperative complications. The pathological diagnosis was pT1bN0M0, pStage Ⅰ. There was no recurrence about 9 months after the surgery.Conclusion: The sophisticated surgical-assisted CTC appeared to be useful in laparoscopic proximal sigmoid colon cancer surgery.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 3","pages":"249-251"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Pancreaticopleural Fistula in a Patient with Metastatic Gastric Cancer]. [一名转移性胃癌患者的胰腺胸膜瘘】。］

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-03-01

Daiki Matsubara, Shuhei Komatsu, Tomoki Konishi, Shun Ito, Ryo Takeda, Soichiro Ogawa, Yoshihisa Matsumoto, Yuji Fujita, Hisataka Matsuo, Yoshiaki Kuriu, Hisashi Ikoma, Katsumi Shimomura, Kazuma Okamoto, Eigo Otsuji

引用次数: 0